Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies

FEBS Lett. 2014 Jan 21;588(2):308-17. doi: 10.1016/j.febslet.2013.11.027. Epub 2013 Nov 26.

Abstract

Monoclonal antibodies (mAbs) are powerful therapeutics, and their characterization has drawn considerable attention and urgency. Unlike small-molecule drugs (150-600 Da) that have rigid structures, mAbs (∼150 kDa) are engineered proteins that undergo complicated folding and can exist in a number of low-energy structures, posing a challenge for traditional methods in structural biology. Mass spectrometry (MS)-based biophysical characterization approaches can provide structural information, bringing high sensitivity, fast turnaround, and small sample consumption. This review outlines various MS-based strategies for protein biophysical characterization and then reviews how these strategies provide structural information of mAbs at the protein level (intact or top-down approaches), peptide, and residue level (bottom-up approaches), affording information on higher order structure, aggregation, and the nature of antibody complexes.

Keywords: FPOP; Hydrogen/deuterium exchange; Ion mobility; Mass spectrometry; Monoclonal antibody; Native ESI; Protein footprinting; Top-down and bottom-up.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / therapeutic use*
  • Biophysical Phenomena*
  • Humans
  • Mass Spectrometry / methods*

Substances

  • Antibodies, Monoclonal